Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cyclerion Therapeutics
Age
30–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient is ambulatory male or female
Patient's body mass index score is \> 20 and \< 40 kg/m\^2 at the Screening Visit
Women of childbearing potential must have a negative pregnancy test at the time of screening and check-in and must agree to use protocol-specified contraception throughout the duration of the study
Patient's health is stable with no clinically significant findings on physical examination
Patient has type 2 (ie, adult onset) diabetes mellitus diagnosed by a physician or nurse practitioner \> 6 months before the Screening Visit, is on a stable glycemic control medication, and protocol specified hemoglobin (Hb)A1c values at the Screening Visit
Patient has hypertension diagnosed by a physician or nurse practitioner \> 6 months before the Screening Visit, and blood pressure (BP) within the protocol's acceptable range
Patients must be on a stable regimen for hypertension control that includes an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), stable for 28 days
You may not be if
Patient has a clinically significant active or unstable medical condition that, in the opinion of the Investigator, would preclude trial participation
Patient is on medication(s) that, when co-administered with a sGC stimulator, could increase the risk of hypotension
Patient has evidence of severe or active end-organ damage
Patient is an active smoker or has used any nicotine-containing products (cigarettes, e-cigarettes, vape pens, cigars, chewing tobacco, gum, patches) during the 6 months before Check-in. Use of nicotine is excluded during the study until after the End of Trial Visit.
Clareo Health | Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension
